| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Gammagard Liquid vs HyQvia
Side-by-side clinical, coverage, and cost comparison for polyradiculoneuropathy, chronic inflammatory demyelinating.Deep comparison between: Gammagard Liquid vs Hyqvia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHyqvia has a higher rate of injection site reactions vs Gammagard Liquid based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hyqvia but not Gammagard Liquid, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gammagard Liquid
Hyqvia
At A Glance
IV infusion or SC injection
Every 3-4 weeks (IV) or weekly (SC)
Immune globulin replacement
SC injection
Every 3-4 weeks
Immune globulin (IgG replacement)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Multifocal motor neuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Primary Immunodeficiency (IV) 300-600 mg/kg every 3-4 weeks by IV infusion; start at 0.5 mL/kg/hr, increase every 30 minutes if tolerated up to 5 mL/kg/hr.
Primary Immunodeficiency (SC) Initial dose 1.37 x previous IV dose divided by weeks between IV doses, given weekly; 20-30 mL/site at 20-30 mL/hr/site (>=40 kg) or 20 mL/site at 15-20 mL/hr/site (<40 kg).
Multifocal Motor Neuropathy 0.5-2.4 g/kg/month by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.
Chronic Inflammatory Demyelinating Polyneuropathy Induction 2 g/kg divided over 2-5 consecutive days, then maintenance 1 g/kg divided over 1-4 consecutive days every 3 weeks by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 600 mg/kg SC every 3 to 4 weeks after initial ramp-up from 1-week to full dose; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose at each infusion site.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Same dose and frequency as prior IGIV treatment SC, typical dosing interval 4 weeks; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose; ramp-up recommended based on tolerability.
Contraindications
- Anaphylactic or severe systemic hypersensitivity to human immune globulin
- IgA deficiency with antibodies to IgA and history of hypersensitivity
- History of anaphylactic or severe systemic reactions to IgG administration
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
- Known systemic hypersensitivity to hyaluronidase including rHuPH20
- Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)
Adverse Reactions
Most common (>=5%) - Primary Immunodeficiency (IV) Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, edema peripheral, pruritus, cardiac murmur
Most common (>=5%) - Primary Immunodeficiency (SC) Infusion site events, headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, pain in extremity
Most common (>=5%) - Multifocal Motor Neuropathy Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, pain in extremity
Most common (>=5%) - Chronic Inflammatory Demyelinating Polyneuropathy Headache, pyrexia, anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis, pain in extremity
Serious Aseptic meningitis (IV for PI), pulmonary embolism, blurred vision (MMN)
Postmarketing Hemolysis, anaphylactic shock, cerebrovascular accident, transient ischemic attack, tremor, myocardial infarction, deep vein thrombosis, hypotension, pulmonary embolism, pulmonary edema, hyperhidrosis, chest pain, transfusion-related acute lung injury, hypersensitivity, myalgia, chills
Most common (>5%) Local infusion site reactions (discomfort/pain, erythema, swelling/edema, pruritus), headache, fatigue, nausea, pyrexia, vomiting
Postmarketing Hypersensitivity, influenza-like illness, infusion site leaking, anaphylactic reaction, tremor, tachycardia, hypotension, infusion related reaction, dyspnea, paresthesia oral, dermatitis allergic, injection site rash, alanine aminotransferase increased
Pharmacology
GAMMAGARD LIQUID supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents and contains antibodies that interact with immune system cells; the mechanism in CIDP may include immunomodulatory effects.
Immune globulin (IgG) replacement product in which the Immune Globulin Infusion (Human), 10% supplies broad-spectrum opsonizing and neutralizing IgG antibodies against bacterial and viral agents, while rHuPH20 transiently depolymerizes subcutaneous hyaluronan to increase tissue permeability, facilitating dispersion and absorption of the full IgG dose administered subcutaneously.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gammagard Liquid
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Hyqvia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Gammagard Liquid
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Hyqvia
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Gammagard Liquid
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Hyqvia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gammagard Liquid.
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Gammagard LiquidView full Gammagard Liquid profile
HyqviaView full Hyqvia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.